Bruce & Co., Inc. Supernus Pharmaceuticals, Inc. Transaction History

Bruce & Co., Inc.

$205 Million
Q2 2024

A detailed history of Bruce & Co., Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bruce & Co., Inc. holds 82,105 shares of SUPN stock, worth $3.1 Million. This represents 1.07% of its overall portfolio holdings.

Number of Shares

82,105

Previous 82,105 -0.0%

Holding current value

$3.1 Million

Previous $2.8 Million 21.57%

% of portfolio

1.07%

Previous 1.38%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$34.93 - $42.03 $349,300 - $420,300	-10,000 Reduced 10.86%	82,105 $2.97 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $932,700 - $1.14 Million	-30,000 Reduced 24.57%	92,105 $3.29 Million
Q3 2022 Nov 15, 2022	SELL	$28.79 - $35.41 $2.3 Million - $2.83 Million	-80,000 Reduced 39.58%	122,105 $4.13 Million
Q2 2022 Aug 09, 2022	SELL	$25.33 - $34.25 $506,599 - $685,000	-20,000 Reduced 9.0%	202,105 $5.84 Million
Q1 2022 May 11, 2022	SELL	$28.51 - $32.9 $5.13 Million - $5.92 Million	-180,000 Reduced 44.76%	222,105 $7.18 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $885,000 - $1.29 Million	50,000 Added 14.2%	402,105 $10.1 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $4.07 Million - $5.94 Million	204,047 Added 137.82%	352,105 $8.35 Million
Q3 2018 Nov 09, 2018	SELL	$42.7 - $56.55 $427,000 - $565,500	-10,000 Reduced 6.33%	148,058 $7.45 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $882,000 - $1.2 Million	-20,000 Reduced 11.23%	158,058 $9.46 Million
Q3 2017 Nov 15, 2017	BUY	$36.75 - $49.65 $6.54 Million - $8.84 Million	178,058	178,058 $7.12 Million

Others Institutions Holding SUPN

# of Institutions

272

Shares Held

60.5M

Call Options Held

47.9K

Put Options Held

13.1K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bruce & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bruce & Co., Inc. with notifications on news.

Account